Welcome to our dedicated page for Entera Bio SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio director Steven D. Rubin reported a share purchase. On February 9, 2026, he bought 10,000 Ordinary Shares of Entera Bio Ltd. at $1.20 per share.
Following this transaction, Rubin beneficially owns 10,000 Ordinary Shares, all held in direct ownership.
Entera Bio Ltd. director Ellis Sean reported buying 18,000 ordinary shares on February 9, 2026. The purchase was coded as an open-market or private purchase at a weighted average price of $1.24 per share, bringing his directly held stake to 178,098 ordinary shares.
The shares were acquired in multiple trades, with prices ranging from $1.18 to $1.299 per share. Sean is listed as a director of Entera Bio, and the filing shows the ownership as held directly rather than through an intermediary entity.
Entera Bio Ltd. director Germano Geno J filed an initial Form 3 reporting no securities beneficially owned in the company. The filing identifies him as a director, with the event date listed as 02/04/2026 and the statement signed by an attorney-in-fact.
Entera Bio Ltd. has appointed pharmaceutical industry veteran Geno J. Germano as Chairman of the Board and a Class III director, effective February 4, 2026. He will serve until the 2026 annual shareholder meeting or until a successor is chosen.
Germano brings more than three decades of leadership experience, including senior roles at Pfizer where he led a roughly $14 billion innovative medicines portfolio, and board positions at multiple biotech companies. He will receive standard non-employee director cash and equity compensation under Entera’s 2018 Equity Incentive Plan.
Gerald Lieberman resigned as Chairman and as a director effective February 4, 2026, with the company stating his resignation did not result from any disagreement over operations, policies, or practices. Entera highlighted this leadership change as it plans 2026 clinical milestones, including a Phase 3 study of EB613 for osteoporosis and a first-in-human study of Long-Acting Oral PTH for hypoparathyroidism.
Entera Bio Ltd. director Steven D. Rubin filed an initial ownership report on Form 3 related to the company. The filing identifies him as a director and states in the explanation section that "No securities are beneficially owned," indicating he reports no current beneficial ownership of Entera Bio securities.
Entera Bio Ltd. entered into an amended and restated collaboration and license agreement with OPKO Health and OPKO Biologics to expand their partnership. The updated agreement now includes joint preclinical and clinical development of a daily long-acting PTH tablet for hypoparathyroidism and other indications, in addition to the existing oral dual agonist GLP‑1/glucagon peptide program. Development costs for the LA‑PTH program will be shared equally between Entera Bio and OPKO, while other material terms of the original agreement remain unchanged.
The company also announced that director Gerald Ostrov will resign effective February 1, 2026, with no disagreements cited regarding operations, policies, or practices. The Board appointed Steven D. Rubin as a Class III director effective the same date, and he will also serve on the compensation committee and as Chairman of the audit committee. The Board determined that Rubin is independent and qualifies as an audit committee financial expert, and he will receive standard non‑employee director compensation.
Entera Bio Ltd. filed details of equity compensation for director Dana Yaacov-Garbeli. On 01/01/2026, the director received 30,157 ordinary shares at a price of $0, bringing total directly held ordinary shares to 77,416. These shares were awarded in lieu of cash fees for services as a director for the 2025 fiscal year.
On the same date, the director was also granted a stock option to buy 33,505 ordinary shares at an exercise price of $1.94 per share, expiring on 01/01/2036. This option represents the Board’s annual option grant to directors and vests ratably on a quarterly basis over a one-year period that began on January 1, 2026. Following these grants, the director beneficially owns 33,505 derivative securities (stock options), all held directly.
Entera Bio Ltd. filed insider transaction details showing equity-based compensation for a company director. On 01/01/2026, the director received 38,294 ordinary shares with par value NIS 0.0000769 per share, reported at a price of $0, in lieu of cash fees for services as a director for the 2025 fiscal year. Following this transaction, the director reported beneficial ownership of 338,454 ordinary shares held directly.
The filing also reports a grant of a stock option on 01/01/2026 to purchase 33,505 ordinary shares at an exercise price of $1.94 per share. These options represent the Board’s annual grant to directors and vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.
Entera Bio (ENTX) filed its Q3 2025 10‑Q, showing a clinical-stage profile with minimal revenue and ongoing losses. For the nine months ended September 30, 2025, revenue was $42 thousand and net loss was $8.4M (loss per share $0.18). In Q3, net loss was $3.2M.
Cash, cash equivalents and restricted cash totaled $16.7M at quarter‑end, including $8.0M held in escrow from OPKO’s equity purchase tied to the 2025 collaboration. Operating cash use was $5.5M year‑to‑date. R&D was $4.3M and G&A $4.2M for the period.
Management states substantial doubt about continuing as a going concern. The company believes existing cash supports operations through the middle of Q3 2026, but starting the EB613 Phase 3 program will require additional funding. The FDA agreed that a single 24‑month Phase 3 with total hip BMD as the primary endpoint could support an NDA for EB613, letting the program advance. Capital actions included net ATM proceeds of $6.1M (2,731,574 shares at a weighted average price of $2.29) and the issuance of 3,685,226 shares to OPKO for $8.0M (escrowed).
Shares outstanding were 45,664,506 as of September 30, 2025, and 45,857,242 as of November 10, 2025.
Entera Bio Ltd. reported consolidated cash, cash equivalents and restricted cash of $18.9 million as of June 30, 2025, up from $9.1 million a year earlier, driven by equity financings and a collaboration payment held in escrow. The company recorded a six‑month net loss of $5.2 million (loss per share $0.12), increasing R&D spend to $2.6 million as it prepares for an EB613 Phase 3 program and advances the OPKO collaboration on oral OXM.
Management states available funds should support operations through the middle of the third quarter of 2026 under current plans but excludes the capital required to initiate the EB613 Phase 3 study, and the filing notes this raises substantial doubt about the company’s ability to continue as a going concern. Material near‑term developments include a $8.0 million issuance to OPKO (3,685,226 shares) placed in escrow to fund collaborative program costs and the FDA’s written concurrence (July 28, 2025) that a single 24‑month multinational Phase 3 with total hip BMD primary endpoint can support an NDA for EB613.